|
1
|
Twelves C, Wong A, Nowacki MP, Abt M,
Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J,
Georgoulias V, et al: Capecitabine as adjuvant treatment for stage
III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shimada Y, Hamaguchi T, Mizusawa J, Saito
N, Kanemitsu Y, Takiguchi N, Ohue M, Kato T, Takii Y, Sato T, et
al: Randomised phase III trial of adjuvant chemotherapy with oral
uracil and tegafur plus leucovorin versus intravenous fluorouracil
and levofolinate in patients with stage III colorectal cancer who
have undergone Japanese D2/D3 lymph node dissection: Final results
of JCOG0205. Eur J Cancer. 50:2231–2240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leichman CG, Lenz H-J, Leichman L,
Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and
Danenberg PV: Quantitation of intratumoral thymidylate synthase
expression predicts for disseminated colorectal cancer response and
resistance to protracted-infusion fluorouracil and weekly
leucovorin. J Clin Oncol. 15:3223–3229. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lenz H-J, Hayashi K, Salonga D, Danenberg
KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S,
Leichman LP, et al: p53 point mutations and thymidylate synthase
messenger RNA levels in disseminated colorectal cancer: An analysis
of response and survival. Clin Cancer Res. 4:1243–1250.
1998.PubMed/NCBI
|
|
5
|
Bathe OF, Franceschi D, Livingstone AS,
Moffat FL, Tian E and Ardalan B: Increased thymidylate synthase
gene expression in liver metastases from colorectal carcinoma:
Implications for chemotherapeutic options and survival. Cancer J
Sci Am. 5:34–40. 1999.PubMed/NCBI
|
|
6
|
Paradiso A, Simone G, Petroni S, Leone B,
Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra
CJ, et al: Thymidilate synthase and p53 primary tumour expression
as predictive factors for advanced colorectal cancer patients. Br J
Cancer. 82:560–567. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujii R, Seshimo A and Kameoka S:
Relationships between the expression of thymidylate synthase,
dihydropyrimidine dehydrogenase, and orotate
phosphoribosyltransferase and cell proliferative activity and
5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin
Oncol. 8:72–78. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ciaparrone M, Quirino M, Schinzari G,
Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G and Barone
C: Predictive role of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase expression in colorectal
cancer patients receiving adjuvant 5-fluorouracil. Oncology.
70:366–377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnston PG, Fisher ER, Rockette HE,
Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role
of thymidylate synthase expression in prognosis and outcome of
adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol.
12:2640–2647. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takenoue T, Nagawa H, Matsuda K, Fujii S,
Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation
between thymidylate synthase expression and survival in colon
carcinoma, and determination of appropriate application of
5-fluorouracil by immunohistochemical method. Ann Surg Oncol.
7:193–198. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edler D, Glimelius B, Hallström M,
Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H:
Thymidylate synthase expression in colorectal cancer: A prognostic
and predictive marker of benefit from adjuvant fluorouracil-based
chemotherapy. J Clin Oncol. 20:1721–1728. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Donada M, Bonin S, Nardon E, De Pellegrin
A, Decorti G and Stanta G: Thymidilate synthase expression predicts
longer survival in patients with stage II colon cancer treated with
5-flurouracil independently of microsatellite instability. J Cancer
Res Clin Oncol. 137:201–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Etienne MC, Chéradame S, Fischel JL,
Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F
and Milano G: Response to fluorouracil therapy in cancer patients:
The role of tumoral dihydropyrimidine dehydrogenase activity. J
Clin Oncol. 13:1663–1670. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB, et al: Colorectal tumors responding to 5-fluorouracil
have low gene expression levels of dihydropyrimidine dehydrogenase,
thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res.
6:1322–1327. 2000.PubMed/NCBI
|
|
15
|
Lassmann S, Hennig M, Rosenberg R, Nährig
J, Schreglmann J, Krause F, Poignee-Heger M, Nekarda H, Höfler H
and Werner M: Thymidine phosphorylase, dihydropyrimidine
dehydrogenase and thymidylate synthase mRNA expression in primary
colorectal tumors-correlation to tumor histopathology and clinical
follow-up. Int J Colorectal Dis. 21:238–247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tokunaga Y, Sasaki H and Saito T: Clinical
role of orotate phosphoribosyl transferase and dihydropyrimidine
dehydrogenase in colorectal cancer treated with postoperative
fluoropyrimidine. Surgery. 141:346–353. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ochiai T, Umeki M, Miyake H, Iida T,
Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H,
et al: Impact of 5-fluorouracil metabolizing enzymes on
chemotherapy in patients with resectable colorectal cancer. Oncol
Rep. 32:887–892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mori T, Ohue M, Takii Y, Hashizume T, Kato
T, Kotake K, Sato T and Tango T: Factors predicting the response to
oral fluoropyrimidine drugs: A phase II trial on the
individualization of postoperative adjuvant chemotherapy using oral
fluorinated pyrimidines in stage III colorectal cancer treated by
curative resection (ACT-01 Study). Oncol Rep. 29:437–444. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koda K, Miyauchi H, Kosugi C, Kaiho T,
Takiguchi N, Kobayashi S, Maruyama T and Matsubara H; Boso Clinical
Oncology Group, : Tumor 5-FU-related mRNA expression and efficacy
of oral fluoropyrimidines in adjuvant chemotherapy of colorectal
cancer. Anticancer Res. 36:5325–5331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Metzger R, Danenberg K, Leichman CG,
Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L
and Danenberg PV: High basal level gene expression of thymidine
phosphorylase (platelet-derived endothelial cell growth factor) in
colorectal tumors is associated with nonresponse to 5-fluorouracil.
Clin Cancer Res. 4:2371–2376. 1998.PubMed/NCBI
|
|
21
|
Tokunaga Y, Hosogi H, Hoppou T, Nakagami
M, Tokuka A and Ohsumi K: Prognostic value of thymidine
phosphorylase/platelet-derived endothelial cell growth factor in
advanced colorectal cancer after surgery: Evaluation with a new
monoclonal antibody. Surgery. 131:541–547. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saito S, Tsuno N, Nagawa H, Sunami E,
Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T and Muto T:
Expression of platelet-derived endothelial cell growth factor
correlates with good prognosis in patients with colorectal
carcinoma. Cancer. 88:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Odin E, Wettergren Y, Nilsson S, Willén R,
Carlsson G, Spears CP, Larsson L and Gustavsson B: Altered gene
expression of folate enzymes in adjacent mucosa is associated with
outcome of colorectal cancer patients. Clin Cancer Res.
9:6012–6019. 2003.PubMed/NCBI
|
|
24
|
Satta T, Isobe K, Yamauchi M, Nakashima I,
Akiyama S, Itou K, Watanabe T and Takagi H: Establishment of drug
resistance in human gastric and colon carcinoma xenograft lines.
Jpn J Cancer Res. 82:593–598. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonner RF, Emmert-Buck M, Cole K, Pohida
T, Chuaqui R, Goldstein S and Liotta LA: Laser capture
microdissection: Molecular analysis of tissue. Science.
278:1481–1483, 1483. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lord RV, Salonga D, Danenberg KD, Peters
JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P,
DeMeester SR, et al: Telomerase reverse transcriptase expression is
increased early in the Barrett's metaplasia, dysplasia,
adenocarcinoma sequence. J Gastrointest Surg. 4:135–142. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bronckaers A, Gago F, Balzarini J and
Liekens S: The dual role of thymidine phosphorylase in cancer
development and chemotherapy. Med Res Rev. 29:903–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Che J, Pan L, Yang X, Liu Z, Huang L, Wen
C, Lin A and Liu H: Thymidine phosphorylase expression and
prognosis in colorectal cancer treated with 5-fluorouracil-based
chemotherapy: A meta-analysis. Mol Clin Oncol. 7:943–952.
2017.PubMed/NCBI
|
